ReviewCancer cell2026
Macrophages: Targets for next-generation cancer immunotherapy.
Review in Cancer cell, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Lipid metabolic reprogramming of macrophage by host APOBEC3 deficiency enhances anti-tumor immunity.British journal of cancer · 2026Article
- Oral Fungal Infection Impacts Epithelial Innate Immunity to Promote Local and Distal Squamous Cell Carcinoma Progression.Cancer research · 2026Article
- Article
- Review
- Review
- 25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap.Cancers · 2026Review
- Single-Cell Glycomics of the Pancreatic Tumor Microenvironment: Technologies, Glyco-Immune Checkpoints, and Tumor-Immune Communication.Advanced biology · 2026Review
- Efficacy of Bioengineered PD-L1 siRNA for Immunotherapy Against Non-Small Cell Lung Cancer Cells.Non-coding RNA · 2026Article
- Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition.Nature communications · 2026Article
- Myeloid cell reprogramming combined with zoledronic acid effectively suppresses bone metastasis.Cancer biology & medicine · 2026Article
- Immune Phenotype in Urothelial Carcinoma: From Tumor Biology to Therapeutic Stratification.Cancers · 2026Review
- Anthraquinone-Loaded Liposomes for TAM Reprogramming in Triple-Negative Breast Cancer: Mechanistic Rationale, Delivery Logic, and Translational Challenges.Pharmaceutics · 2026Review
- Targeting CDK4/6 potentiates the efficacy of anti-CD47 therapy via modulating the suppressive function of tumor-associated macrophages.Apoptosis : an international journal on programmed cell death · 2026Article
- Degrading Immune Checkpoints and Coordinating Oncogenic Signaling: Emerging Strategies in Cancer Therapy.ACS medicinal chemistry letters · 2026Article
- Pan-cancer analysis in the real-world setting uncovers immunogenomic drivers of acquired resistance post-immunotherapy.Journal for immunotherapy of cancer · 2026Article
- LNP-based delivery of a Toll-like receptor 9 agonist elicits potent adjuvant effects and antitumor immunity.NPJ vaccines · 2026Article
- Transmembrane lectins in cancer immunity: emerging drivers of myeloid-mediated immunosuppression.Frontiers in immunology · 2026Review
- Overcoming immunotherapy barriers in pediatric brain tumors: epigenetic strategies.Frontiers in oncology · 2026Review
- Sex differences in innate immune cell responses: Impact on cancer immunity and response to therapy.Frontiers in immunology · 2026Review
- Macrophage polarization in gynecologic malignancies: key signaling pathways and clinical perspectives.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tumor-associated macrophages (TAM) are among the most abundant immune cells in tumors and exhibit striking functional plasticity, enabling them to either promote tumor progression or mediate malignant cell elimination. This paradox arises from TAM heterogeneity shaped by diverse developmental origins, transcriptional programs, and microenvironmental cues. Here, we review next-generation strategies to therapeutically target TAMs, with dual goals of relieving macrophage-driven immunosuppression and unleashing their tumoricidal potential. These approaches include effectorization by modulating "eat-me" pathways and targeted activation, as well as reprogramming TAMs through inhibiting immune checkpoints, rewiring signaling, epigenetics, and metabolism, and targeting myeloid progenitors at sites of hematopoiesis. We also discuss advances in bioengineering, including bispecific antibodies, masked cytokines, genetic engineering, targeted lipid nanoparticles and anti-TAM CAR T cells, that enable increasingly precise control of macrophage biology. These therapies have transformative potential to enhance tumor-specific T cells, and provide an independent alternative arm of immunity, to enable durable cancer eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.